Gammaplex IVIG is for intravenous (IV) infusion only and must be administered by a qualified healthcare professional in a clinical setting (e.g., hospital, infusion center). It is not for self-administration at home.
- Preparation: Gammaplex IVIG is supplied as a ready-to-use liquid solution (10% concentration). It should be visually inspected for particulate matter and discoloration before administration; it should appear clear or slightly opalescent and colorless to pale yellow. Do not use if it is cloudy or contains particles. The solution should be brought to room temperature before infusion. Do not dilute Gammaplex IVIG with other intravenous fluids, but if dilution is absolutely necessary (e.g., for very small pediatric patients), only 5% Dextrose in Water (D5W) should be used.
- Administration Procedure: Gammaplex IVIG is administered directly into a vein using an infusion pump.
- Infusion Rate: The infusion should always start at a slow initial rate (e.g., 0.3 mg/kg/min for the first 30 minutes). If the patient tolerates the infusion well, the rate can be gradually increased in increments, up to a maximum recommended rate (e.g., 1.2 mg/kg/min for PI patients, or higher for ITP depending on tolerance). For patients at higher risk of adverse reactions (e.g., those with pre-existing renal dysfunction, cardiovascular disease, or elderly), a slower infusion rate is crucial and should be maintained throughout the infusion.
- Monitoring During Infusion: Patients are closely monitored for any signs of adverse reactions, especially during the initial phase and when the infusion rate is increased. Vital signs (blood pressure, heart rate, temperature, respiratory rate) are frequently checked.
- Dedicated IV Line: Gammaplex IVIG should be administered via a separate intravenous line. It should not be mixed with other intravenous medications or solutions. The line can be flushed with 5% Dextrose in Water (D5W) or 0.9% Sodium Chloride for Injection.
The specific dose, frequency, and duration of treatment are determined by the prescribing physician based on the individual patient’s condition, weight, and clinical response.
Gammaplex IVIG exerts its therapeutic effects through different mechanisms, depending on the indication:
- Passive Immunization (for PI): In Primary Immunodeficiency, where the body’s natural antibody production is insufficient, Gammaplex IVIG directly supplies a comprehensive array of functional IgG antibodies. These passively transferred antibodies target and neutralize a wide range of bacterial, viral, and other microbial pathogens and their toxins. This provides immediate immune protection, helping to prevent and fight off infections.
- Immunomodulation (for ITP): In Chronic Immune Thrombocytopenic Purpura, the high doses of IgG in Gammaplex IVIG primarily act as immunomodulators. The exact mechanisms are not fully understood but are believed to involve:
- Fc Receptor Blockade: The Fc (constant) portion of the IgG molecules can bind to and saturate Fc receptors on macrophages (immune cells that typically destroy antibody-coated platelets). This blockade prevents the destruction of antibody-coated platelets, leading to an increase in platelet count.
- Neutralization of Autoantibodies: The diverse antibody repertoire may include anti-idiotypic antibodies that can neutralize or interfere with the activity of pathogenic autoantibodies that mistakenly attack platelets.
- Other Immunomodulatory Effects: It may also influence cytokine production, modulate complement activation, and affect the function of B and T lymphocytes, contributing to a rebalancing of the immune response.
Upon intravenous infusion, the IgG is rapidly distributed throughout the body, providing immediate systemic availability.
Like all medications, Gammaplex IVIG can cause side effects. Most common reactions are typically mild to moderate and infusion-related, but serious adverse events can occur.
Common Side Effects (often infusion-related, generally mild to moderate):
- Headache
- Fever
- Chills (rigors)
- Flushing (warmth or redness)
- Nausea
- Vomiting
- Fatigue
- Dizziness
- Back pain, muscle pain (myalgia), joint pain (arthralgia)
- Changes in blood pressure (increase or decrease)
- Chest discomfort
These common reactions are often associated with the rate of infusion and may frequently be minimized by slowing down the infusion rate or by pre-medicating with antihistamines or acetaminophen.
Serious Side Effects (less common, but require immediate medical attention):
- Severe Hypersensitivity/Anaphylaxis: Rare but potentially life-threatening allergic reactions, including severe hives, difficulty breathing, swelling of the face, lips, tongue, or throat, severe dizziness, chest tightness, or fainting. This risk is higher in IgA-deficient patients who have antibodies to IgA.
- Acute Renal Dysfunction/Failure: Can occur, particularly in predisposed patients (pre-existing kidney disease, diabetes, dehydration, advanced age, or concomitant use of nephrotoxic drugs). Symptoms may include decreased urination, sudden weight gain, or swelling of the hands/feet.
- Thromboembolic Events (Blood Clots): These can include stroke, myocardial infarction (heart attack), deep vein thrombosis (DVT), and pulmonary embolism (PE). Symptoms include chest pain, shortness of breath, sudden numbness or weakness, or pain/swelling in an arm or leg.
- Aseptic Meningitis Syndrome (AMS): A rare, non-infectious inflammation of the lining around the brain and spinal cord, characterized by severe headache, stiff neck, fever, photophobia (light sensitivity), nausea, and vomiting. Usually occurs within hours to 2 days after infusion.
- Hemolysis: Destruction of red blood cells, which can lead to anemia. Signs include dark urine, pale skin, yellowing of the skin or eyes, and unusual tiredness.
- Transfusion-Related Acute Lung Injury (TRALI): A severe, non-cardiogenic pulmonary edema that can cause acute respiratory distress, typically within 1 to 6 hours of infusion.
- Volume Overload: Especially in patients with cardiac or renal impairment, rapid infusion or large volumes can lead to symptoms like shortness of breath, rapid breathing, and swelling.
- Hyperproteinemia, Increased Serum Viscosity, and Pseudohyponatremia: These can occur and may contribute to other adverse events like thrombosis.
Any new, severe, or worsening symptoms experienced during or after infusion should be reported to a healthcare provider immediately.
Gammaplex IVIG carries several important warnings and precautions that healthcare providers must consider to ensure patient safety.
- Boxed Warning (Thrombosis, Renal Dysfunction, Acute Renal Failure): Like all immune globulin products, Gammaplex IVIG carries a boxed warning due to the potential for:
- Thrombosis (Blood Clots): Thrombotic events may occur. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Administer Gammaplex IVIG at the minimum dose and infusion rate practicable for patients at risk. Ensure adequate hydration before administration.
- Renal Dysfunction and Acute Renal Failure: Acute renal dysfunction and failure can occur. The risk is elevated in predisposed patients (those with pre-existing renal insufficiency, diabetes mellitus, age over 65, volume depletion, sepsis, paraproteinemia, or concomitant use of nephrotoxic drugs). Ensure adequate hydration and monitor renal function (BUN/creatinine).
- Hypersensitivity/Anaphylaxis: Gammaplex IVIG is contraindicated in individuals with a history of anaphylactic or severe systemic hypersensitivity reactions to human immune globulin. It is also contraindicated in IgA-deficient patients with known antibodies to IgA due to the increased risk of severe anaphylaxis. Epinephrine and other emergency medical support must be immediately available during administration.
- Aseptic Meningitis Syndrome (AMS): This can occur following IVIG treatment. Patients should be monitored for its signs and symptoms (severe headache, stiff neck, fever, photophobia, nausea, vomiting).
- Hemolysis: Gammaplex IVIG contains blood group antibodies (e.g., anti-A, anti-B) that can cause a positive direct antiglobulin test (Coombs’ test) and hemolysis (destruction of red blood cells). Monitor patients for clinical signs and symptoms of hemolysis and delayed hemolytic anemia, especially those with non-O blood group or pre-existing anemia.
- Transfusion-Related Acute Lung Injury (TRALI): A severe, non-cardiogenic pulmonary edema that can cause acute respiratory distress. Patients should be monitored for pulmonary adverse reactions.
- Transmission of Infectious Agents: Despite stringent donor screening, plasma testing, and validated viral inactivation/removal processes (including solvent/detergent treatment and nanofiltration), a theoretical risk of transmitting infectious agents (e.g., viruses, variant Creutzfeldt-Jakob disease [vCJD] agent, and theoretically, the Creutzfeldt-Jakob disease [CJD] agent) cannot be completely eliminated.
- Interference with Live Virus Vaccines: Antibodies can interfere with the immune response to live attenuated virus vaccines.
- Interference with Laboratory Tests: Passively transferred antibodies can lead to false-positive serological tests or interfere with certain laboratory assays (e.g., blood grouping).
- Hyperproteinemia, Increased Serum Viscosity, and Pseudohyponatremia: These can occur. Patients should be monitored for these changes, and pseudohyponatremia (false low sodium due to high protein) should be distinguished from true hyponatremia to avoid inappropriate fluid management.
Gammaplex IVIG can interact with other medications, primarily affecting certain vaccines and potentially increasing the risk of adverse effects with specific drugs.
- Live Virus Vaccines: The antibodies present in Gammaplex IVIG can interfere with the development of an adequate immune response to live attenuated virus vaccines (e.g., Measles, Mumps, Rubella [MMR], Varicella [chickenpox], Yellow Fever). Therefore, vaccination with live virus vaccines should generally be deferred for at least 6 months (and potentially up to 11 months, depending on the specific vaccine and the dose of Gammaplex IVIG administered) after Gammaplex IVIG infusion. Patients should always consult their healthcare provider regarding appropriate vaccination schedules.
- Nephrotoxic Drugs: Concomitant use with other medications known to be harmful to the kidneys (nephrotoxic drugs), such as certain antibiotics (e.g., aminoglycosides) or loop diuretics, may increase the risk of acute kidney injury. Close monitoring of renal function (e.g., BUN and serum creatinine) is recommended when these drugs are co-administered.
- Interference with Laboratory Tests: The passive transfer of antibodies from Gammaplex IVIG can lead to false-positive serological test results (e.g., for certain viral infections) or interfere with specific assay readings, such as blood grouping or the direct antiglobulin test (Coombs’ test), potentially leading to misleading interpretations.
Patients should always inform their healthcare provider and pharmacist about all prescription medications, over-the-counter drugs, herbal remedies, and supplements they are taking or plan to take.
The dosage of Gammaplex IVIG is highly individualized based on the specific indication, the patient’s body weight, and their clinical response. It is administered intravenously.
- Primary Humoral Immunodeficiency (PI):
- Dose: Typically 300 to 800 mg/kg (0.3 to 0.8 g/kg) body weight, administered every 3 to 4 weeks.
- Adjustment: Dosage and frequency are adjusted based on the patient’s clinical response (e.g., reduction in infection rate) and to achieve desired IgG trough serum levels (often aiming for trough levels above 500-800 mg/dL).
- Infusion Rate: Initial rate usually 0.3 mg/kg/min for 30 minutes. If tolerated, the rate can be gradually increased to a maximum of 1.2 mg/kg/min.
- Chronic Immune Thrombocytopenic Purpura (ITP):
- Dose: 1 g/kg (1000 mg/kg) body weight, given as a single dose. Up to two such doses may be administered depending on the platelet count response. If an adequate increase in platelet count is observed after the first 1 g/kg dose, the second dose may be withheld.
- Infusion Rate: Initial rate usually 0.3 mg/kg/min for 30 minutes. If tolerated, the rate can be gradually increased to a maximum of 1.2 mg/kg/min.
General Infusion Considerations:
- Ensure patients are adequately hydrated before the infusion, especially for higher doses or in patients at risk for renal dysfunction or thrombosis.
- For patients at increased risk (e.g., elderly, renal impairment, cardiovascular disease, hyperviscosity), the lowest practicable dose and infusion rate should be used.
- Close monitoring of vital signs and for adverse reactions is essential throughout the entire infusion.
Gammaplex IVIG is a prescription-only medication (POM). It is a complex biological product, and its use is subject to stringent medical and regulatory oversight.
- Specialist Prescribing: Gammaplex IVIG must be prescribed by a licensed medical professional, typically a specialist such as an immunologist, hematologist, or other physician experienced in the diagnosis and management of the conditions for which it is indicated.
- Confirmed Diagnosis: A definitive medical diagnosis for one of its approved indications (Primary Immunodeficiency or Chronic ITP) is required, supported by appropriate clinical criteria and laboratory evaluations.
- Medical Necessity and Prior Authorization: Due to its significant cost and specialized application, Gammaplex IVIG often requires prior authorization from insurance providers. This typically involves submitting detailed clinical documentation to justify its medical necessity.
- Administration by Healthcare Professional: As an intravenous infusion, Gammaplex IVIG must be prepared and administered by trained healthcare professionals in a controlled medical environment (e.g., hospital, infusion center, or qualified outpatient clinic). It is never for self-administration.
- Comprehensive Monitoring Plan: The prescribing physician is responsible for establishing and overseeing a thorough monitoring plan for patients receiving Gammaplex IVIG. This includes:
- Efficacy Monitoring: Regular assessment of clinical response (e.g., infection rates in PI, platelet counts in ITP) and relevant laboratory parameters (e.g., IgG trough levels for PI patients).
- Safety Monitoring: Close monitoring of vital signs during infusion, and periodic laboratory tests (e.g., kidney function, complete blood counts) to screen for potential adverse reactions such as acute renal dysfunction, hemolysis, or thrombosis.
- Blood Product Origin: As Gammaplex IVIG is derived from human plasma, it falls under strict regulatory guidelines concerning donor screening and manufacturing processes to ensure product safety. This further reinforces its prescription-only status.
